Characterization and binding activity of the chondroitin/dermatan sulfate chain from Endocan, a soluble endothelial proteoglycan

Glycobiology

Volumn 20, Issue 11, 2010, Pages 1380-1388

  Sarrazin, Stphane ^a,e   Lyon, Malcolm ^b   Deakin, Jon A ^b   Guerrini, Marco ^c   Lassalle, Philippe ^d   Delehedde, Maryse ^d   Lortat Jacob, Hugues ^a  

^a INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^d INSTITUT PASTEUR DE LILLE   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chondroitin sulfate; dermatan sulfate; Endocan; glycosaminoglycan; proteoglycan

Indexed keywords

CHONDROITIN; DERMATAN SULFATE; DISACCHARIDE; ENDOCAN; GLYCOSAMINOGLYCAN; N ACETYLGALACTOSAMINE; N ACETYLGALACTOSAMINE 4 SULFATASE; PROTEOGLYCAN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PURIFICATION;

BINDING SITES; CELLS, CULTURED; CHONDROITIN; CHROMATOGRAPHY, GEL; DERMATAN SULFATE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PROTEOGLYCANS;

TETRA;

EID: 77957846104     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwq100     Document Type: Article

References (38)

1. Abid MR, Yi X, Yano K, Shih SC, Aird WC. 2006. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res. 72:136-145.
2. Adam E, Sarrazin S, Landolfi C, Motte V, Lortat-Jacob H, Lassalle P, Delehedde M. 2008. Efficient long-term and high-yielded production of a recombinant proteoglycan in eukaryotic HEK293 cells using a membrane-based bioreactor. Biochem Biophys Res Commun. 369:297-302.
3. Basappa, Murugan S, Sugahara KN, Lee CM, ten Dam GB, van Kuppevelt TH, Miyasaka M, Yamada S, Sugahara K. 2009. Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells. Glycobiology. 19:735-742.
4. Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, Janin A, Tonnel A, Lassalle P. 2000. Characterization of the secreted form of en-dothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res. 37:417-425.
5. Bechard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, Vazeux R, Richet C, Degand P, Jude B, et al. 2001a. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem. 276:48341-48349.
6. Bechard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, Pestel J, Dessaint JP, Tonnel AB, Lassalle P. 2001b. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 167:3099-3106.
7. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 68:729-777.
8. Bishop JR, Schuksz M, Esko JD. 2007. Heparan sulphate proteoglycans finetune mammalian physiology. Nature. 446:1030-1037.
9. Borczuk AC, Shah L, Pearson GD, Walter KL, Wang L, Austin JH, Friedman RA, Powell CA. 2004. Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med. 170:167-174.
10. Catlow KR, Deakin JA, Wei Z, Delehedde M, Fernig DG, Gherardi E, Gallagher JT, Pavao MS, Lyon M. 2008. Interactions of hepatocyte growth factor/scatter factor with various glycosaminoglycans reveal an important interplay between the presence of iduronate and sulfate density. J Biol Chem. 283: 5235-5248.
11. Deakin JA, Blaum BS, Gallagher JT, Uhrin D, Lyon M. 2009. The binding properties of minimal oligosaccharides reveal a common heparan sulfate/dermatan sulfate-binding site in hepatocyte growth factor/scatter factor that can accommodate a wide variety of sulfation patterns. J Biol Chem. 284:6311-6321.
12. Depontieu F, Grigoriu BD, Scherpereel A, Adam E, Delehedde M, Gosset P, Lassalle P. 2008. Loss of Endocan tumorigenic properties after alternative splicing of exon 2. BMC Cancer. 8:14.
13. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, Lafitte JJ, Copin MC, Tonnel AB, Lassalle P. 2006. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res. 12: 4575-4582.
14. Guerrini M, Naggi A, Guglieri S, Santarsiero R, Torri G. 2005. Complex glyco-saminoglycans: Profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem. 337:35-47.
15. Huang GW, Tao YM, Ding X. 2009. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci. 54:389-394.
16. Iozzo RV. 1998. Matrix proteoglycans: From molecular design to cellular function. Annu Rev Biochem. 67:609-652.
17. Iozzo RV. 2005. Basement membrane proteoglycans: From cellar to ceiling. Nat Rev Mol Cell Biol. 6:646-656.
18. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, Devos R, Tonnel AB. 1996. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 271:20458-20464.
19. Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, Villers A, Delehedde M, Copin MC, Lassalle P. 2010. Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology. 56: 180-187.
20. Li F, Ten Dam GB, Murugan S, Yamada S, Hashiguchi T, Mizumoto S, Oguri K, Okayama M, van Kuppevelt TH, Sugahara K. 2008. Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells. J Biol Chem. 283:34294-34304.
21. Lyon M, Deakin JA, Lietha D, Gherardi E, Gallagher JT. 2004. The interactions of hepatocyte growth factor/scatter factor and its NK1 and NK2 variants with glycosaminoglycans using a modified gel mobility shift assay. Elucidation of the minimal size of binding and activatory oligosaccharides. J Biol Chem. 279:43560-43567.
22. Malavaki C, Mizumoto S, Karamanos N, Sugahara K. 2008. Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. Connect Tissue Res. 49:133-139.
23. Maurage CA, Adam E, Mineo JF, Sarrazin S, Debunne M, Siminski RM, Baroncini M, Lassalle P, Blond S, Delehedde M. 2009. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol. 68:633-641.
24. Morgan MR, Humphries MJ, Bass MD. 2007. Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol. 8:957-969.
25. Mucci A, Schenetti L, Volpi N. 2000. 1H and 13C nuclear magnetic resonance identification and characterization of components of chondroitin sulfates of various origin. Carbohydr Polym. 41:37-45.
26. Mulloy B, Forster MJ. 2000. Conformation and dynamics of heparin and heparan sulfate. Glycobiology. 10:1147-1156.
27. Nandini CD, Sugahara K. 2006. Role of the sulfation pattern of chondroitin sulfate in its biological activities and in the binding of growth factors. Adv Pharmacol. 53:253-279.
28. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, Westholm JO, Komorowski J, Lassalle P, Cross MJ, et al. 2007. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res. 313: 1285-1294.
29. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M. 2006. Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 1765:25-37.
30. Scherpereel A, Gentina T, Grigoriu B, Senechal S, Janin A, Tsicopoulos A, Plenat F, Bechard D, Tonnel AB, Lassalle P. 2003. Overexpression of en-docan induces tumor formation. Cancer Res. 63:6084-6089.
31. Shin JW, Huggenberger R, Detmar M. 2008. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endo-thelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood. 112: 2318-2326.
32. Tsai JC, Zhang J, Minami T, Voland C, Zhao S, Yi X, Lassalle P, Oettgen P, Aird WC. 2002. Cloning and characterization of the human lung endotheli-al-cell-specific molecule-1 promoter. J Vasc Res. 39:148-159
33. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:530-536.
34. Wasteson A. 1971. A method for the determination of the molecular weight and molecular-weight distribution of chondroitin sulphate. J Chromatogr. 59:87-97.
35. Wegrowski Y, Maquart FX. 2006. Chondroitin sulfate proteoglycans in tumor progression. Adv Pharmacol. 53:297-321.
36. Xian X, Gopal S, Couchman JR. 2010. Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue Res. 339:31-46.
37. Yamada S, Sugahara K. 2008. Potential therapeutic application of chondroitin sulfate/dermatan sulfate. Curr Drug Discov Technol. 5:289-301.
38. Yoneda A, Couchman JR. 2003. Regulation of cytoskeletal organization by syndecan transmembrane proteoglycans. Matrix Biol. 22:25-33.